XNASPHAT
Market cap512mUSD
Dec 24, Last price
7.50USD
1D
-1.45%
1Q
-57.51%
IPO
-68.21%
Name
Phathom Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
751.95
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
43.00%
Rev. gr., 5y
%
Revenues
682k
Net income
-202m
L-9.60%
CFO
-138m
L-6.11%
Earnings
Mar 05, 2025
Profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 682 | |||||
Cost of revenue | 50,066 | 173,060 | 135,601 | |||
Unusual Expense (Income) | ||||||
NOPBT | (49,384) | (173,060) | (135,601) | |||
NOPBT Margin | ||||||
Operating Taxes | 25,283 | 4,211 | ||||
Tax Rate | ||||||
NOPAT | (49,384) | (198,343) | (139,812) | |||
Net income | (201,592) -9.60% | (223,006) 50.58% | (148,094) 11.08% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 155,463 | 24,596 | 1,290 | |||
BB yield | -33.20% | -5.60% | -0.18% | |||
| Debt | ||||||
Debt current | 726 | 708 | 487 | |||
Long-term debt | 139,492 | 98,168 | 92,524 | |||
Deferred revenue | ||||||
Other long-term liabilities | 309,516 | 117,025 | 7,500 | |||
Net debt | (241,175) | (57,014) | (90,248) | |||
| Cash flow | ||||||
Cash from operating activities | (137,580) | (146,530) | (148,617) | |||
CAPEX | (1,634) | (1,041) | (328) | |||
Cash from investing activities | (1,634) | (1,041) | (328) | |||
Cash from financing activities | 367,580 | 120,042 | 44,708 | |||
FCF | (49,511) | (199,273) | (139,017) | |||
| Balance | ||||||
Cash | 381,393 | 155,385 | 183,259 | |||
Long term investments | 505 | |||||
Excess cash | 381,359 | 155,890 | 183,259 | |||
Stockholders' equity | (928,680) | (727,090) | (529,367) | |||
Invested Capital | 1,304,467 | 866,371 | 700,364 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 51,289 | 39,118 | 37,003 | |||
Price | 9.13 -18.63% | 11.22 -42.96% | 19.67 -40.79% | |||
Market cap | 468,269 6.69% | 438,906 -39.70% | 727,848 -34.06% | |||
EV | 227,094 | 381,892 | 637,600 | |||
EBITDA | (48,809) | (172,440) | (135,080) | |||
EV/EBITDA | ||||||
Interest | 41,968 | 27,305 | 6,788 | |||
Interest/NOPBT | ||||||